title: Medullary breast carcinoma: prognostic implications of p53 expression.
abstract: Medullary breast carcinoma (MBC) is a rare pathological type of breast cancer. The rate of p53 protein accumulation is higher in MBC than in common invasive ductal carcinoma. Whether this particular feature of MBC influences the outcome after treatment is unknown. We retrospectively analyzed the characteristics, treatment and outcome of 71 patients with MBC treated between 1981 and 1996. The median age was 51 years (range 27-81) and the median clinical tumor size was 25 mm (range 0-70 mm). Breast-conserving treatment was offered when possible: 55 patients had undergone a tumorectomy and radiotherapy while 16 patients had undergone a mastectomy. p53 protein accumulation was determined by immunohistochemistry on paraffin-embedded tumor specimens from 58/71 samples available for this study. The median follow-up for the 56 survivors was 113 months (range 30-241). The 10-year survival and metastasis-free survival rates were 81% and 81.4%, respectively. The local recurrence rate was 16.4%. The two factors predicting outcome were pathological axillary node involvement in the 60 patients who underwent axillary dissection and adjuvant chemotherapy. p53 accumulation was found in 33/58 patients (57%). p53 status was not predictive of survival nor of distant or local recurrences. We confirm that medullary breast carcinoma has a favorable prognosis despite its aggressive pathological features. p53 protein accumulation, found in the majority of MBCs, was not related to outcome.
authors.affiliation: Department of Radiotherapy, Institut Curie, Paris, France. remi.dendale@curie.net
authors.forename: R
authors.initials: R
authors.lastname: Dendale
authors.forename: A
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: E
authors.initials: E
authors.lastname: Mouret-Fourme
authors.forename: A
authors.initials: A
authors.lastname: Savignoni
authors.forename: J
authors.initials: J
authors.lastname: Medioni
authors.forename: F
authors.initials: F
authors.lastname: Campana
authors.forename: J R
authors.initials: JR
authors.lastname: Vilcoq
authors.forename: A
authors.initials: A
authors.lastname: de la Rochefordière
authors.forename: T
authors.initials: T
authors.lastname: Soussi
authors.forename: B
authors.initials: B
authors.lastname: Asselain
authors.forename: P
authors.initials: P
authors.lastname: de Cremoux
authors.forename: A
authors.initials: A
authors.lastname: Fourquet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000401:mortality; D018276:Carcinoma, Medullary / Q000737:chemistry* / Q000235:genetics / Q000401:mortality; D005260:Female; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D016159:Tumor Suppressor Protein p53